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AbstrAct
Objective Diminished cardiac high-energy phosphate 
metabolism (phosphocreatine-to-ATP (PCr:ATP) ratio) 
and cardiac power with age may play an important roles 
in development of cardiac dysfunction and heart failure. 
The study defines the impact of age on PCr:ATP ratio and 
cardiac power and their relationship.
Methods Thirty-five healthy women (young≤50 years, 
n=20; and old≥60 years, n=15) underwent cardiac 
MRI with 31P spectroscopy to assess PCr:ATP ratio and 
performed maximal graded cardiopulmonary exercise 
testing with simultaneous gas-exchange and central 
haemodynamic measurements. Peak cardiac power 
output, as the best measure of pumping capability and 
performance of the heart, was calculated as the product 
of peak exercise cardiac output and mean arterial blood 
pressure.
results PCr:ATP ratio was significantly lower in 
old compared with young age group (1.92±0.48 vs 
2.29±0.55, p=0.03), as were peak cardiac power 
output (3.35±0.73 vs 4.14±0.81W, p=0.01), diastolic 
function (ie, early-to-late diastolic filling ratio, 1.33±0.54 
vs 3.07±1.84, p<0.01) and peak exercise oxygen 
consumption (1382.9±255.0 vs 1940.3±434.4 mL/
min, p<0.01). Further analysis revealed that PCr:ATP 
ratio shows a significant positive relationship with 
early-to-late diastolic filling ratio (r=0.46, p=0.02), peak 
cardiac power output (r=0.44, p=0.02) and peak oxygen 
consumption (r=0.51, p=0.01).
conclusions High-energy phosphate metabolism and 
peak power of the heart decline with age. Significant 
positive relationship between PCr:ATP ratio, early-to-
late diastolic filling ratio and peak cardiac power output 
suggests that cardiac high-energy phosphate metabolism 
may be an important determinant of cardiac function 
and performance.
IntrOductIOn
Heart failure is a clinical syndrome associated with 
cardiac dysfunction at rest and/or in response to 
stress. Neubauer proposed that the heart failure 
is ‘an engine out of fuel’ and diminished cardiac 
high-energy phosphate metabolism plays an 
important role in the mechanisms of heart failure.1 
The heart has one of the largest metabolic demands 
in the body and it uses chemical energy stored in 
phosphoryl bonds of metabolites from its primary 
substrate (ie, fatty acid, carbohydrate and ketone 
bodies) to maintain its contractile function.2 ATP 
followed by phosphocreatine (PCr) are the two most 
important high-energy phosphates in the heart.2 
Derangements in cardiac metabolism deprive the 
heart of high-energy phosphates required to main-
tain its function and performance and may cause 
mechanical failure of the heart.3 Studies have also 
shown that all components of cardiac metabolism 
(ie, substrate utilisation, mitochondrial oxidative 
phospshorylation, high-energy phosphate metab-
olism and PCr:ATP ratio) are impaired in heart 
failure.1 4 5 Experimental studies using various 
animal models demonstrated the link between 
cardiac energetics and cardiac function.6 7 Glucose 
6-phosphate dehydrogenase (G6PD) is a major key 
enzyme in NAPDH generation, and G6PD-deficient 
mice exhibited diminished contractile function and 
high oxidative stress.6 Improvement in cardiac 
metabolism may lead to better cardiac function, 
whereas diminished cardiac energy metabolism is a 
cause of heart failure.6
Currently, limited number of clinical studies 
have investigated the association between cardiac 
high-energy phosphate metabolism and cardiac 
function and performance. In particular, no 
study reported the relationship between PCr:ATP 
ratio and peak cardiac power output, which is 
proposed to be the best indicator of overall func-
tion and pumping capability of the heart, and the 
strongest predictor of prognosis in heart failure.8 
Better understanding of the interaction between 
metabolism and function of the heart may lead 
to development of new treatment strategies to 
improve clinical outcomes. Therefore, the aim of 
the present study is to first, define the effect of age 
on cardiac high-energy phosphate metabolism and 
peak cardiac power output and second, assess the 
relationship between PCr:ATP ratio and cardiac 
function and performance. Because of a signifi-
cant gender difference in age-associated changes in 
cardiac morphology and function,9 we designed this 
study to address the relationship between cardiac 
metabolism and performance in women.
MethOds
study design
This was a single-centre, cross-sectional, observa-
tional study.
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Participants
Thirty-five healthy women were recruited as volunteers for 
the study and grouped according to age (young ≤50 years old, 
n=20; and old ≥60 years old, n=15). Subjects were included 
in the study only if they (1) had no history of cardiovascular 
disease, pulmonary diseases and other chronic diseases and (2) 
had normal glucose tolerance and lipid profile, normal resting 
blood pressure, normal ECG and body mass index ≤30 kg/m2. 
Subjects were excluded from the study if they (1) were current 
or past smokers; (2) were taking any medication known to affect 
cardiovascular function or (3) were not able to perform maximal 
graded cardiopulmonary exercise stress test. All participants 
signed an informed consent according to the Declaration of 
Helsinki, and the study was approved by the National Health 
Service North East England—Tyne and Wear South.
Procedures
All study participants underwent cardiac MRI examination using 
a 3.0T Philips Intera and a 6-channel cardiac coil (Philips; Best, 
Netherlands (NL)) with ECG gating. Patients were asked to lie 
in a supine position and hold their breath while images were 
obtained in a short axis view. A ViewForum workstation (Philips) 
was used for cardiac analysis. Epicardial and endocardial borders 
were manually traced at end-systole and end-diastole on the 
short axis slices to calculate measures of cardiac function and 
structure. Contour selection and calculation of left-ventricular 
mass, systolic and diastolic parameters were performed following 
previously used protocol.10 11
Cardiac high-energy phosphate metabolism was assessed using 
31P magnetic resonance spectroscopy. Data were collected using 
a 10 cm diameter 31P surface coil (Pulseteq, UK) for transmission/
reception of signal. Subjects were placed in a prone position. 
Shimming was performed using a cardiac triggered, breath-held 
field map. A slice-selective, cardiac-gated 1-dimensional chemical 
shift imaging (1D-CSI) sequence was used with a 7 cm slice selec-
tive pulse applied foot head to eliminate contamination from the 
liver, with spatial presaturation of lateral skeletal muscle. Sixteen 
coronal phase-encoding steps were used, yielding spectra from 
10 mm slices (repitition time (TR) = heart rate, 192 averages at 
the centre of k-space with acquisition weighting and ~20 min 
acquisition time). Spectral locations were overlaid onto an 
anatomical image, and the first spectrum arising entirely beyond 
the chest wall was selected. Quantification of PCr, the γ reso-
nance of ATP and 2,3-diphosphoglycerate (DPG) was performed 
using the AMARES time-domain fit routine in the jMRUI-pro-
cessing software. Corrections for saturation, flip angle and blood 
ATP content were made as published previously.12
In addition to cardiac MRI, all participants performed 
maximal graded cardiopulmonary exercise test on an elec-
tromagnetically controlled semirecumbent cycle ergometer. 
Throughout the exercise test, gas exchange measurement system 
(Metalyzer 3B, Cortex, Leipzig, Germany) and the bioreactance 
method (NICOM, Cheetah Medical, Delaware) were used to 
non-invasively measure gas exchange and central haemody-
namics. The bioreactance method accurately measures frequency 
of relative phase shift of oscillating electronic current across the 
thorax, and we have recently reported its validity and reliability 
to assess cardiac output at rest and during exercise.13–16 It has 
greater signal-to-noise ratio by 100-fold compared with the 
older bioimpedance method and is less susceptible to disrup-
tion from excessive movements, adipose tissue and electrode 
placement.15 Throughout the test, 12-lead electrocardiogram 
(Custo, CustoMed, GmbH, Ottobrunn, Germany) and blood 
pressure (Tango, SunTech Medical; Morrisville, North Carolina, 
USA) were recorded. During the exercise test, participants were 
asked to cycle at 20 W for 3 min as a warm-up period, followed 
by increase in workload of 10 W per minute, until volitional 
exhaustion. Cardiopulmonary exercise test was terminated when 
(1) subject has reached volitional exhaustion, that is inability to 
pedal at cadence of 50 revolutions per minute; (2) maximal 
oxygen consumption was achieved, that is there was no further 
increase in oxygen utilisation despite increase in exercise inten-
sity (watts); (3) respiratory exchange ratio >1.15 or (4) subject 
voluntarily terminated the test. Cardiac power output, expressed 
in watts, was calculated as the product of peak exercise cardiac 
output and mean arterial blood pressure.8 Cardiac reserve was 
defined as the difference between peak and resting cardiac 
power output. Peak oxygen consumption, as a measure of meta-
bolic response, was defined as the average oxygen uptake during 
the last minute of exercise.
Physical activity level and number of steps were assessed 
objectively using a validated portable multisensor array (Sense-
wear, Bodymedia, Pennsylvania). The monitor was worn for 7 
days and was only removed for bathing.
statistical analysis and sample size
All statistical analysis was carried out using SPSS V.21.0. Prior 
to statistical analysis, data were tested for univariate and multi-
variate outliers using standard Z-distribution cut-offs and 
Mahalanobis distance tests. Kolmogorov-Smirnov test was 
used to assess normality of distribution. Differences between 
age groups were assessed using t-test. Pearson coefficient of 
correlation was used to assess the relationship between vari-
ables. Statistical significance was indicated if p<0.05. Data are 
presented as mean ± SD unless stated otherwise. A previous 
study, in which a similar outcome was used, reported a mean 
difference of 0.24 in PCr:ATP ratio to be significant between 
younger and older age groups.17 To show this difference with 
at least 70% power at the 5% significance, we needed data for 
a total of 28 participants (ie, ≥14 participants per age group). 
table 1 Participant demographic and clinical measures
All participants Young (≤50 years old, n=20) Older (≥60 years old, n=15) p Value
Age (years) 55.7±14.0 (40–81) 44.4±3.2 (40–50) 70.9±5.7 (63–81) 0.00
Weight (kg) 67.7±11.2 (45–93) 69.2±12.3 (53–93) 65.6±9.6 (45–82) 0.35
Height (cm) 163.0±5.8 (149–175) 166.0±4.8 (155–175) 159.2±4.7 (149–165) 0.00
Body mass index (kg/m2) 25.5±3.7 (17.9–30.4) 25.2±4.0 (19–30.4) 25.9±3.4 (18–29.8) 0.59
Body surface area (m2) 1.7±0.1 (1.5–2.1) 1.8±0.1 (1.6–2.2) 1.7±0.1 (1.5–1.9) 0.06
Fat body mass (kg) 23.6±9.1 (5.3–34.1) 22.7±10.1 (5.8–34.1) 24.8±7.7 (5.3–31.2) 0.51
Physical activity (steps/day) 11532±5422 (7694–16348) 11578±4985 (7882–16348) 11651±5012 (7694–15854) 0.72
Mean ± SD (range).
p Indicates difference between young and older group.
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We have therefore recruited 35 participants (15 younger and 20 
older) for the study.
results
Data were normally distributed and not outliers were identified 
in variables of interests. Participants’ demographic details are 
presented in table 1. Anthropometric measures were not signifi-
cantly different between young and old groups except height. 
Other measures, such as weight, body mass index, body surface 
area, fat body mass and lean body mass, were not significantly 
different between the two groups (p>0.05). The level of phys-
ical activity (number of steps per day) was also not significantly 
different between younger and older women (table 1).
the effect of age on cardiac structure, function and 
metabolism
Cardiac MRI revealed that left-ventricular mass and early-to-late 
diastolic filling ratio were significantly lower in older women 
compared with younger women (78.6±9.7 vs 90.7±16.1 g 
p=0.01; and 1.3±0.5 vs 3.1±1.8, p<0.01, table 2). More impor-
tantly, older women demonstrated significantly lower PCr:ATP 
ratio compared with younger women (1.9±0.5 vs 2.3±0.6, 
p=0.03, table 2, figure 1A).
Resting measures taken prior to cardiopulmonary exercise test 
revealed that metabolic measures that is, oxygen consumption 
and respiratory exchange ratio, were not significantly different 
between young and old groups (p>0.05, table 3). Resting 
cardiac variables such as stroke volume and cardiac output 
were significantly lower in the older age group (70.3±7.9 vs 
87.1±14.4 mL/beats, p<0.01 and 4.9±0.8 vs 61.1±1.2 L/
min, p<0.01). Older women also demonstrated higher systolic 
blood pressure and systemic vascular resistance (142.9±12.5 vs 
128.5±16.8 mm Hg, p=0.01 and 1765±336 vs 1352±266 
dyne/s/cm5, p<0.01; table 3)
At peak exercise, older women exhibited significantly lower 
oxygen consumption compared with younger women (21.5±4.6 
vs 28.6±8.8 mL/kg/min, p<0.01, table 4). Older women 
also showed significantly lower peak heart rate (140±15 vs 
169±10 beats/min, p<0.01), peak cardiac output (11.9±2.3 
vs 15.4±3.0 L/min, p<0.01) and peak cardiac power output 
(3.3±0.7 vs 4.1±0.8 W, p=0.01, table 4, figure 1B). Figures 2 
and 3 present box-plots (median, first and third quartiles) for 
the rest and peak exercise variables, that is oxygen consumption, 
cardiac power output, cardiac index, heart rate, mean arterial 
blood pressure and systemic vascular resistance.
relationship between age and cardiac metabolism, function 
and performance
Age was significantly associated with decline in PCr:ATP 
ratio (r=−0.40, p=0.03), early-to-late diastolic filling ratio 
(r=−0.74, p<0.01) and cardiac output (r=−0.35, p=0.04). 
There was a significant positive relationship between age and 
resting systolic blood pressure (r=0.47, p=0.02) and systemic 
vascular resistance (r=0.42, p=0.03).
At peak exercise, age was significantly associated with lower 
heart rate (r=−0.82, p<0.01), cardiac output (r=−0.60, 
p<0.01), cardiac power output (r=−0.44, p<0.01) and oxygen 
consumption (r=−0.70, p<0.01). There was however a positive 
relationship between age and peak exercise systolic blood pres-
sure (r=0.38, p=0.04) and systemic vascular resistance (r=0.64, 
p<0.01).
relationship between cardiac metabolism and cardiac 
function and performance
There was no significant relationship between PCr:ATP ratio 
and measures of cardiac structure and function, except for early-
to-late diastolic filling ratio as a measure of diastolic function 
(r=0.46, p=0.02). Further analysis revealed a significant rela-
tionship between PCr:ATP ratio and measures of cardiac perfor-
mance, that is peak cardiac power output (r=0.44, p=0.02, 
figure 4A), peak heart rate (r=0.42, p=03, figure 4B), peak 
oxygen consumption (r=0.51, p=0.01, figure 4C), cardiac 
output (r=0.45, p=0.01) and cardiac reserve (r=0.42, p=0.03). 
There was a significant negative relationship between PCr:ATP 
ratio and systemic vascular resistance (r=−0.39, p=0.04, 
figure 4D). PCr:ATP ratio was significantly correlated with 








old, n=15) p Value
Left ventricular mass (g) 85.5±14.9 90.7±16.1 78.6±9.7 0.01
Eccentricity ratio (g/mL) 0.8±0.1 0.8±0.1 0.8±0.1 0.16
Left-ventricular ejection 
fraction (%)
61.7±7.7 58.7±7.6 65.8±5.8 0.01
PCr:ATP ratio 2.1±0.5 2.3±0.6 1.9±0.5 0.03
Longitudinal shortening 
(%)
19.4±5.9 19.4±3.0 19.5±4.9 0.92
E:A ratio 2.3±1.7 3.1±1.8 1.3±0.5 0.00
E;A,early-to-late diastolic  filling ratio; PCr:ATP, phosphocreatine-to-ATP.
Figure 1 Cardiac high-energy phosphate metabolism—phosphocreatine-to-ATP ratio (A) and cardiac pumping capability—cardiac power output 
(B) in young and older women.
group.bmj.com on July 7, 2017 - Published by http://heart.bmj.com/Downloaded from 
4 nathania M, et al. Heart 2017;0:1–8. doi:10.1136/heartjnl-2017-311275
cardiac risk factors and prevention
systolic blood pressure at rest (r=−0.36, p=0.04), but not at 
peak exercise (r=−0.22, p=0.09).
dIscussIOn
This is the first study to address the relationship between high-en-
ergy phosphate metabolism and maximal performance of the 
heart assessed in response to cardiopulmonary exercise testing. 
The study is clinically relevant as it helps better understand 
the role of high-energy phosphate metabolism in overall func-
tion and performance of the heart, further supporting previous 
suggestion that diminished cardiac metabolism is a potential 
mechanisms responsible for the development of cardiac dysfunc-
tion and heart failure.1 The major finding of this study suggests 
that cardiac high-energy phosphate metabolism, as measured 
by PCr:ATP ratio, is significantly correlated with measures of 
diastolic function and performance of the heart. In addition, the 
study findings demonstrate that cardiac metabolism, function 
and performance of the heart decline with age.
Results from previous studies evaluating changes in cardiac 
metabolism with age are conflicting. Okada et al and Köstler 
et al18 19 reported significant decline in PCr and ATP levels 
in older subjects compared with younger subject. However, 
a decline in the PCr:ATP ratio was not observed. Our find-
ings support recent studies reporting that PCr:ATP ratio 
decreases with age,11 17 20 that is older women demonstrate 
significantly lower PCr:ATP ratio compared with younger 
women and that this decline in cardiac metabolism is nega-
tively correlated with age. The decline in cardiac high-energy 
phosphate metabolism possibly reflects a number of age-asso-
ciated changes including a decrease in mitochondrial oxidative 
phosphorylation, impaired myocardial lysosomes and decline 
in creatine kinase activity with age.21 Oxidative phosphoryla-
tion is responsible for 95% of cardiac ATP production; thus, a 
decline in oxidative phosphorylation will lead to the decrease 
in overall cardiac high-energy metabolism. Creatine kinase is 
a catalytic enzyme that is crucial in the regeneration of ATP 
table 3 Resting gas exchange and central haemodynamics measures
All participants Young (≤50 years old, n=20) Old (≥60 years old, n=15) p Value
Resting metabolic variables
  Oxygen consumption (mL/min) 244.3±35.9 250.2±40.9 236.5±27.4 0.20
  Oxygen consumption (mL/kg/min) 3.7±0.7 3.7±0.9 3.7±0.5 0.81
  Respiratory exchange ratio 0.9±0.1 0.9±0.1 0.9±0.1 0.90
Resting haemodynamics
  Heart rate (beats/min) 69.9±7.6 69.6±7.6 70.3±7.9 0.80
  Stroke volume (mL/beat) 80.1±16.2 87.1±14.4 70.8±14.1 0.00
  Stroke volume index (mL/beat/m2) 46.2±8.3 49.4±8.0 42.1±6.8 0.01
  Cardiac output (L/min) 5.6±1.2 6.1±1.2 4.9±0.8 0.00
  Cardiac index (L/min/m2) 3.2±0.6 3.4±0.6 2.9±0.4 0.00
  Systolic blood pressure (mm Hg) 134.7±16.6 128.5±16.8 142.9±12.5 0.01
  Diastolic blood pressure (mm Hg) 86.0±9.9 85.6±9.9 86.7±10.1 0.75
  Mean arterial blood pressure (mm Hg) 102.2±10.7 99.9±10.7 105.4±10.2 0.13
  Cardiac power output (W) 1.3±0.3 1.4±0.3 1.2±0.2 0.06
  Cardiac power output index (W/m2) 0.7±0.2 0.8±0.2 0.7±0.1 0.13
  Systemic vascular resistance (dyne/(s·cm5)) 1529.0±359.0 1352.1±265.6 1764.9±336 0.00
table 4 Peak exercise gas exchange and central haemodynamic measures
All participants Young (≤50 years old, n=20) Old (≥60 years old, n=15) p Value
Peak exercise metabolic variables
  Oxygen consumption(mL/min) 1701.4±458.9 1940.3±434.4 1382.9±255.0 0.00
  Oxygen consumption (mL/kg/min) 25.5±8.0 28.6±8.8 21.5±4.6 0.00
  Arterial-venous oxygen difference (mLO2) 12.5±2.9 12.9±3.4 11.9±2.2 0.31
  Respiratory exchange ratio 1.2±0.1 1.2±0.1 1.2±0.1 0.55
  Peak exercise haemodynamics
  Heart rate (beats/min) 156.5±19.5 169.2±10.4 139.6±15.4 0.00
  Stroke volume (mL/beat) 89.5±19.0 92.5±20.0 85.6±17.5 0.29
  Stroke volume index (mL/beat/m2) 51.8±9.9 52.5±10.9 50.8±8.7 0.63
  Cardiac output (L/min) 13.9±3.2 15.4±3.0 11.9±2.3 0.00
  Cardiac index (L/min/m2) 8.0±1.8 8.8±1.7 7.1±1.3 0.00
  Systolic blood pressure (mm Hg) 188.9±20.3 182.5±21.1 197.6±16.0 0.03
  Diastolic blood pressure (mm Hg) 90.9±11.3 90.5±12.7 91.4±9.4 0.81
  Mean arterial blood pressure (mm Hg) 123.6±10.1 121.1±10.2 126.8±9.3 0.10
  Cardiac power output (W) 3.8±0.9 4.1±0.8 3.3±0.7 0.01
  Cardiac power output index (W/m2) 2.2±0.5 2.4±0.5 2.0±0.4 0.03
  Cardiac reserve (W) 2.5±0.9 2.8±0.9 2.2±0.8 0.05
  Systemic vascular resistance (dyne/(s·cm5)) 750.9±191.8 651.2±137.8 883.8±174.6 0.00
group.bmj.com on July 7, 2017 - Published by http://heart.bmj.com/Downloaded from 
5nathania M, et al. Heart 2017;0:1–8. doi:10.1136/heartjnl-2017-311275
cardiac risk factors and prevention
from ADP and PCr, and its decline with age may lead to subse-
quent decrease in PCr level.18 Previous studies also reported an 
age-associated elevated increase in lipofuscine and decreased 
lysosomal efficiency leading to subsequent death of cardiac 
myocytes.17 Kates et al22 also reported a decline in myocardial 
fatty acid utilisation and oxidation with no change in glucose 
utilisation, which consequently lead to diminished overall 
cardiac high-energy phosphate metabolism.
Measures of cardiac function and performance change 
with age that is, decreased early-to-late diastolic filling ratio, 
cardiac output and cardiac power output, whereas systemic 
blood pressure and left-ventricular ejection fraction increased. 
These age-related haemodynamic changes have been previ-
ously reported. The increase in systolic blood pressure is due 
to accumulation of collagen and calcium in the large arteries, 
along with loss of elastic fibres from the medial layer.22 23 The 
thickening and stiffening of large arteries increase systemic 
vascular resistance, thus leading to raised systolic blood pres-
sure. A decrease in early-to-late diastolic filling ratio with age 
occurs due to age-associated decline in left-ventricular early 
diastolic filling rate and increase in late diastolic ventricular 
filling.24 Early diastolic filling rate has been observed to decline 
progressively after the age of 20 and diminished to 50% by 80 
years of age.24 An increase in late diastolic ventricular filling 
with age occurs due to increased atrial contribution to ventric-
ular filling.25 Also, decline in diastolic function occurs due to a 
number of age-associated changes such as myocardial collagen 
accumulation, matrix proliferation, reduced calcium overload 
threshold and reduced ventricular length.26 These changes 
increase wall stress and reduce cardiac contractility, leading to 
subsequent decline in diastolic function.
This study shows that cardiac high-energy phosphate metabolism 
has a positive and significant relationship with early-to-late diastolic 
filling ratio, peak cardiac output, peak cardiac power output and 
cardiac reserve. This suggests that a decline in cardiac high-energy 
phosphate metabolism might lead to age-related decline in cardiac 
function and performance. It should also be noted that PCr:ATP 
ratio was negatively correlated with systolic blood pressure and 
systematic vascular resistance. As blood pressure is an important 
determinant of cardiac energy consumption, it potentially may 
Figure 2 Cardiac and metabolic responses from rest to peak exercise in younger and older women: Oxygen consumption in young (A) and old (B); 
cardiac power output in young (C) and old (D); cardiac index in young (E) and Old (F).
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explain observed reduction in PCr:ATP ratio in older women, as 
previously suggested.27
This is the first human study to define the relationship 
between high-energy metabolism and overall maximal function 
and pumping capability of the heart represented by peak cardiac 
power. Peak cardiac power has been proposed to be the best 
indicator of overall cardiac function because it integrates both 
flow-generating and pressure-generating capacities of the heart, 
and as a such has been shown to be the strongest predictor of 
prognosis in heart failure.11
Our findings therefore support previous theory suggesting 
that diminished cardiac metabolism may play a significant role 
in mechanisms of development of cardiac dysfunction and heart 
failure.1 Previous animal studies have shown that alterations 
in cardiac high-energy phosphate metabolism lead to reduced 
contraction velocity, diminished systolic function and reduced 
cardiac contractility.6 7 However, the exact mechanism of how 
cardiac metabolism leads to diminished cardiac function and 
performance still need to be defined. Fundamentally, ATP 
hydrolysis is a key in driving the myosin head sliding move-
ment along actin filament during contraction.28 Diminished 
cardiac high-energy phosphate metabolism will lead to reduced 
cardiac high-energy phosphates. The rates of myocardial ATP 
production must closely matched the cardiac metabolic demand. 
A halt in ATP production would deplete cardiac ATP stores in 
mere 15 s.2 Therefore, decline in ATP production may affect 
cardiac contractility and viability and highly likely cause dimin-
ished cardiac function and performance. Moreover, a decline 
in PCr level might disrupt cardiac contractility. During inade-
quate oxygenation, PCr and ADP is rapidly converted into ATP 
through the rapid and reversible creatine kinase reaction.29 This 
is essential to maintain high levels of ATP and low levels of 
ADP. When energy demand outweighs supply, PCr level falls to 
maintain normal levels of ATP, with an increase in ADP level.5 29 
Elevated free ADP inhibits intracellular enzymes and disrupts 
cardiac contractile function.
This study is not without limitations. Only women were studied 
due to the significant differences in age-associated changes in cardiac 
morphology and function between men and women as previously 
confirmed.9 Further larger mechanistic studies to include both 
women and men are required to provide better understanding of 
the interaction between cardiac energetics and function.
Figure 3 Cardiac responses from rest to peak exercise in younger and older women: Heart rate in young (A) and old (B); mean arterial blood 
pressure in young (C) and old (D); systematic vascular resistance in young (E) and old (F).
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cOnclusIOn
High-energy phosphate metabolism and performance of the 
heart decline with age. A significant positive relationship between 
PCr:ATP ratio and peak cardiac power output suggests that 
cardiac high-energy phosphate metabolism may be an important 
determinant of cardiac function and performance.
Key messages
What is already known on this subject?
Age-related decline in high-energy phosphate metabolism 
and cardiac performance may play an important role in 
the development of cardiac dysfunction and heart failure.
What might this study add?
This study demonstrates a significant positive relationship 
between phosphocreatine-to-ATP ratio and peak cardiac power, 
suggesting that cardiac high-energy phosphate metabolism 
may be an important determinant of cardiac function and 
performance.
how might this impact on clinical practice?
Therapeutic interventions known to improve cardiac metabolism 
may lead to improvement in overall cardiac function.
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